RxDoctor Payments DataLook up a doctor →

Richard Adler, MD

Ophthalmology · Baltimore, MDNPI 1629076179

Payments from drug & device makers

$2,737,297in general payments, 2019–2025

Across 2,892 payments — averaging $946.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$889K
  • Sun Pharmaceutical Industries Inc.$442K
  • Tarsus Pharmaceuticals, Inc.$322K
  • Oyster Point Pharma, Inc.$218K
  • Harrow Eye, LLC$197K
  • Bausch & Lomb Americas Inc.$192K
  • plus $478K from 15 others

What the payments were for

  • Consulting fees$320,09112%
  • Speaking & faculty fees$2,014,81474%
  • Travel & lodging$354,31513%
  • Food & beverage$48,0772%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,737,297 in reported general payments places this provider in the 95th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$99,752
Medicare patients
290
Services billed
762

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine28$45,497
XdemvyLotilaner25$45,400
LumiganBimatoprost47$24,004
TyrvayaVarenicline Tartrate34$21,898
XiidraLifitegrast24$21,267
VevyeCyclosporine20$14,537
CequaCyclosporine18$13,826
MieboPerfluorohexyloctane/Pf16$11,444
Cyclosporine22$11,010
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol12$3,025
Latanoprost144$2,126
Prednisolone Acetate30$1,512
Brimonidine Tartrate53$434
Ofloxacin23$365
Ketorolac Tromethamine11$319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$888,987$69,50175 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$321,855$45,40025 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$192,161$32,71140 claims
Oyster Point Pharma, Inc.Tyrvaya$217,629$21,89834 claims
Harrow Eye, LLCVevye$197,009$14,53720 claims
Sun Pharmaceutical Industries Inc.Cequa$441,745$13,82618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →